Virtual Lecture
Integrating New Therapies Into the Treatment of Advanced Prostate Cancer
Release Date: March 20, 2021
Expiration Date: March 19, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
Three experts in genitourinary malignancies examine management of advanced prostate cancer in 2021. New agents, new combinations, and the data to support best practices and guidelines make this forum an important resource for clinicians. The critical roles of shared decision-making and patient-centered care—including optimizing the management of potential adverse effects of treatment to improve adherences—merge science with real-world clinical practice.
Format
Interactive video lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Evaluate current and emerging clinical trial data for therapies for prostate cancer
- Integrate novel therapies into the treatment of patients with advanced prostate cancer based on patient and disease factors, as well as efficacy and safety evidence
- Implement strategies to monitor and manage adverse events of novel treatments for prostate cancer
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Eleni Efstathiou, MD, PhD
- Associate Professor
- Department of Genitourinary
- Medical Oncology
- Division of Cancer Medicine
- University of Texas
- MD Anderson Cancer Center
- Houston, Texas
Terran W. Sims, ACNP-BC, MSN, CNN, COCN
- Nurse Practitioner
- Genitourinary Oncology, Urology
- Faculty
- University of Virginia School of Nursing
- AG-ACNP Program
- University of Virginia
- Charlottesville, Virginia
Matthew R. Smith, MD, PhD
- Professor of Medicine
- Harvard Medical School
- Director
- Genitourinary Malignancies Program
- Massachusetts General Hospital Cancer Center
- Boston, Massachusetts
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 19, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA Course Advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was developed from a live program cosupported by educational grants from AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck & Co., Inc.; and Taiho Oncology, Inc.
This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Efstathiou: advisory board/consultant/research support: Astellas, Bayer, Janssen, Merck, Myovant Sciences, ORIC Pharmaceuticals, Pfizer, Sanofi.
Ms Sims has no relevant financial relationships to disclose.
Dr Smith: consultant: Amgen, Bayer, Lilly, Janssen, Pfizer.
Ms Williams: speakers bureau: AstraZeneca.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms. Williams as noted above.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: March 20, 2021
Expiration date: March 19, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100320BTC-7A